hcp.loloestrin.comLo Loestrin® Fe | For Healthcare Providers

FOR U.S. HEALTHCARE PROFESSIONALS ONLY Important Safety Information Prescribing Information Patient Site LO LOESTRIN FE REQUEST SAMPLES MENU Home Why Lo Loestrin Fe? Prescribing Considerations Prescribing Considerations Is Lo Loestrin Fe Right for Her? HCP Resources HCP Support Request Samples Savings Program Request a Representative Formulary Coverage Patient Site Why Lo Loestrin Fe? Prescribing Considerations Prescribing Considerations Is Lo Loestrin Fe Right for Her? HCP Resources HCP Support Request Samples Savings Program Request a Representative Formulary Coverage Lo Loestrin® Fe is indicated for pregnancy prevention* Lo Loestrin Fe is the # 1 - PRESCRIBED oral contraceptive by OB/GYNs 1 WHY LO LOESTRIN FE? REQUEST SAMPLES FORMULARY COVERAGE LO LOESTRIN® FE SAVINGS PROGRAM Lo Loestrin Fe is indicated for effective pregnancy prevention with a Pearl Index of 2.92 (95% CI: 1.94-4.21) * ,† The Lowdown on Lo Lo Lo Loestrin Fe is the only available ultra-low-dose oral contraceptive (OC) with just 10 mcg of daily estrogen 2 Unique 24/2/2 regimen 2 with a 2-day hormone-free interval Lo Loestrin Fe has no generic equivalent available 3 * The efficacy of Lo Loestrin Fe in women with a body mass index (BMI) >35 kg/m 2 has not been evaluated. 2,† † 1-Year (thirteen 28-day cycles), multicenter, open-label study of 1270 women aged 18 to 35 years that was designed to assess the efficacy of Lo Loestrin Fe for a total of 12,482 twenty-eight day evaluable cycles of exposure. The efficacy of Lo Loestrin Fe in women with a BMI > 35 kg/m 2 has not been evaluated. The weight range for those women treated was 89 to 260 lbs with a mean weight of 150 lbs. 2 Lo Loestrin Fe may provide short, lighter periods 2,4 Mean duration of withdrawal bleeding was < 2 days per cycle Patient-reported intensity of withdrawal bleeding was lighter than normal LEARN MORE ABOUT LO LOESTRIN FE A survey ‡ of more than 1000 current and potential OC users found that 4 : 93% are interested § in an OC with the lowest amount of daily estrogen 78% worry || about the amount of hormones they are exposed to through the use of OCs ‡ Source: Online survey conducted by Harris Poll on behalf of Allergan USA, Inc., between July 7-14, 2014, among 1005 U.S. women aged 18-45 currently using OCs or considering use in the next 6 months. § Survey respondents could choose from the following to indicate their interest in an OC with the lowest amount of daily estrogen: extremely interested, very interested, somewhat interested, and not at all interested. The 93% value represents those who answered extremely interested, very interested, and somewhat interested. || Survey respondents could choose from the following to indicate their level of worry about the amount of hormones they are exposed to through the use of OCs: extremely worried, very worried, somewhat worried, and not at all worried. The 78% value represents those who answered extremely worried, very worried, and somewhat worried. PRESCRIBING CONSIDERATIONS Lo Loestrin Fe is widely covered 5 and available at $0 out-of-pocket cost for many patients 4 93% of commercially insured patients can get Lo Loestrin Fe without restrictions from their insurance plans 5, ¶ ˜ 57% of Lo Loestrin Fe prescriptions were filled at $0 out-of-pocket cost 4,# ¶ Source: Symphony Health. Managed Markets Vantage™, Nov 2018-Jan 2019. Data are subject to change. # Source: Data on file. Allergan USA, Inc.: Madison, NJ. Data are not guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits are determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. Allergan does not endorse any individual plans. Formulary coverage does not imply efficacy or safety. CHECK FORMULARY COVERAGE LEARN MORE ABOUT LO LOESTRIN FE Request Samples Formulary Coverage Lo Loestrin® Fe Savings Program INDICATIONS AND USAGE Lo Loestrin® Fe is an estrogen/progestin combination oral contraceptive (COC) indicated for use by women to prevent pregnancy. The efficacy of Lo Loestrin Fe in women with a body mass index (BMI) of >35 kg/m 2 has not been evaluated. IMPORTANT SAFETY INFORMATION Warning: cigarette smoking and serious cardiovascular events Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke. Contraindications Lo Loestrin Fe is contraindicated in pregnant patients, in women with a high risk of arterial or venous thrombotic diseases, liver tumors (benign or malignant) or liver disease, undiagnosed abnormal uterine bleeding, or breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past, and in women using Hepatitis C drugs containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. Warnings and Precautions Discontinue Lo Loestrin Fe if a thrombotic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Lo Loestrin Fe should not be started any earlier than 4 weeks after delivery, in women who are not breastfeeding. If jaundice occurs, treatment should be discontinued. Lo Loestrin Fe should not be prescribed for women with uncontrolled hypertension or hypertension with vascular disease. Women who are pre-diabetic or diabetic should be monitored while using Lo Loestrin Fe. Alternate contraceptive methods should be considered for women with uncontrolled dyslipidemia. Patients using Lo Loestrin Fe who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated. Adverse Reactions In the clinical trial for Lo Loestrin Fe, serious adverse reactions included deep vein thrombosis, ovarian vein thrombosis, and cholecystitis. The most common adverse reactions (incidence ≥2%) were nausea/vomiting, headache, bleeding irregularities, dysmenorrhea, weight fluctuation, breast tenderness, acne, abdominal pain, anxiety, and depression. Patients should be counseled that COCs do not protect against HIV infection (AIDS) and other sexually transmitted diseases. Please see full Prescribing Information, including Boxed Warning , for Lo Loestrin Fe. REFERENCES 1. &nbspIQVIA™. National Prescription Audit® - TRx/EUTRx Data: April 2018 - April 2019 (claim derived from the use of information under license from IQVIA, which expressly reserves all rights, including rights of copying, distribution, and republication). 2. Lo Loestrin® Fe prescribing information. Irvine, CA: Allergan USA, Inc.; 2017. 3. U.S. Food and Drug Administration. The Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/. Accessed January 8, 2019. 4. Data on file. Allergan USA, Inc.: Madison, NJ. 5. Managed Markets Insight and Technology, LLC™, a trademark of MMIT. Database as of September 2018. Data are subject to change. 6. The Alan Guttmacher Institute. Fulfilling the promise: public policy and U.S. family planning clinics. http://www.guttmacher.org/pubs/fulfill.pdf. Accessed January 31, 2018. 7. Junel® Fe 1/20 prescribing information. Sellersville, PA: Teva Pharmaceuticals USA; 2014. 8. Archer OF, Nakajima ST, Sawyer AT, et al. Obstet Gynecol . 2013;122(3):601-607. 9. Ogden CL, Carroll MD, Kit BK, Flegal KM. JAMA . 2014;311(8):806-814. 10. Nakajima ST, Archer DF, Ellman H. Contraception . 2007;75(1):16-22. 11. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Contraception . 2006;74(2):100-103. 12. Spona J, Elstein M, Feichtinger W, et al. Contraception . 1996;54(2):71-77. Are you a U.S. healthcare professional? You are about to enter a site that is for U.S. healthcare professionals only. By selecting “Yes” below, you certify that you are a healthcare...